MRTX News and Press, Mirati Therapeutics Inc. From 12/22/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: shutterstock.com/Nixx Photography Chinese electric vehicle (EV) stocks are a chief concern among investors today as these shares see mixed trading. Investors continue to watch Chinese stocks like a hawk for sign...

Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer PR Newswire U.S. Food and...

Summary Today, we revisit a small, promising oncology concern whose stock is down in recent months due to some strategic changes. However, the company's primary drug candidate is targeting several indications in combination therapy with large potential markets. We update the investm...

Summary Zai Lab Limited is a relative new entrant to the Chinese pharma space and has multiple approvals and a large clinical pipeline. Founder Samantha Du seems willing and capable at driving commercialization partnerships with foreign entities. Also, the in-house pipeline is set t...

The U.S. Food and Drug Administration (FDA) approved Agilent Technologies' ( NYSE: A ) Agilent Resolution ctDx FIRST as a companion diagnostic (CDx) to Mirati Therapeutics ( NASDAQ: MRTX ) Krazati which was approved yesterday to treat certain patients with non-small cell ...

The U.S. Food and Drug Administration (FDA) approved Qiagen's ( NYSE: QGEN ) therascreen KRAS RGQ PCR kit as a companion diagnostic test to Mirati Therapeutics ( NASDAQ: MRTX ) Krazati which was approved yesterday to treat non-small cell lung cancer (NSCLC). ...

Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation PR Newswire SAN DIEGO , Dec. 12, 202...

The US FDA has approved Mirati Therapeutics' ( NASDAQ: MRTX ) Krazati (adagrasib) a second-line treatment for non-small cell lung cancer, Bloomberg reported. The oral small molecule inhibitor of KRAS is for previously treated KRAS G12C –positive patients. Shares are...

Mirati Therapeutics ( NASDAQ: MRTX ) is down 11% in Thursday morning trading, the third day in a row it is in the red. The stock's decline follows phase 2 data on its candidate adagrasib in combination with Merck's ( MRK ) Keytruda (pembrolizumab) in non-small cell lung ca...

Shares of Mirati Therapeutics (NASDAQ: MRTX) slumped more than 28% on Wednesday. The clinical-stage biotech specializes in antibody therapies to treat cancer. The stock has been falling all week. On Monday, the company released early phase 2 data on Adagrasib to treat non-small ce...